Investor Presentaiton

Guardant360 Response can determine which patients are responding to therapies sooner than CT-Scans INVESTOR 20 DAY 23 ctDNA and RECIST identify responders... Molecular responders RECIST responders ...but ctDNA identifies them 8 weeks earlier GUARDANT™ 41% 36% 33% 24% 44% 44% Study A (solid tumors) Study A (NSCLC) Study C (solid tumors) 0 7 Median of 8 weeks ctDNA response RECIST response 15

View entire presentation